# FUS P525L Research Report **Protein:** FUS P525L **Variant:** P525L **UniProt ID:** P35637 **Disease Association:** ALS / FTD **Report Generated:** 2026-07-27 18:24 UTC **AlphaFold Confidence (pLDDT):** 50.3% **Structure Folded:** 2026-07-16 --- ## Structure Summary This analysis examines FUS protein containing the P525L mutation, which is linked to aggressive forms of ALS and frontotemporal dementia. The AlphaFold prediction shows predominantly low structural confidence (average pLDDT 50.3), with only 23% of residues reaching high confidence, reflecting FUS's intrinsically disordered nature. This disorder is actually critical for FUS's normal function in RNA processing and stress response, but the P525L mutation disrupts proper cellular localization, causing toxic protein accumulation in motor neurons that leads to neurodegeneration. --- This AlphaFold structure predicts the conformation of FUS (Fused in Sarcoma) protein carrying the pathogenic P525L variant associated with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The confidence metrics reveal a predominantly disordered structure: an average pLDDT of 50.3 with only 23% of residues achieving high confidence scores (≥70). These low confidence values are biologically meaningful rather than prediction failures—FUS is an intrinsically disordered protein (IDP), a class of proteins that lack stable tertiary structure under physiological conditions. Structurally, FUS contains multiple functional domains including an N-terminal low-complexity domain enriched in glycine, serine, and glutamine residues (visible in the first 65 residues shown), which drives liquid-liquid phase separation for formation of membraneless organelles like stress granules. The repetitive SYGQ motifs observed in the sequence (residues 13-65) are characteristic of the prion-like domain that enables reversible aggregation. The protein's disordered regions facilitate dynamic protein-RNA interactions essential for RNA splicing, transport, and stress response. The P525L mutation occurs near the C-terminus in FUS's nuclear localization signal (NLS). While this region isn't visible in the truncated structure provided, this single amino acid change from proline to leucine dramatically impairs nuclear import by disrupting recognition by the importin machinery. Consequently, mutant FUS accumulates in the cytoplasm where it forms pathological aggregates and sequesters RNA-binding proteins, depriving cells of normal FUS nuclear functions while gaining toxic cytoplasmic functions. For ALS/FTD, this mutation is particularly significant: P525L is among the most aggressive FUS mutations, causing juvenile-onset ALS with rapid progression. The cytoplasmic mislocalization leads to motor neuron death through multiple mechanisms including disrupted RNA metabolism, impaired DNA damage response, and formation of stress granules that fail to properly dissolve. The intrinsic disorder of FUS, normally advantageous for its cellular functions, becomes pathogenic when localization is disrupted—the same flexible regions that enable RNA binding also promote irreversible aggregation in the wrong cellular compartment. The low confidence throughout most of the structure accurately reflects FUS's conformational heterogeneity in solution. Any regions showing moderate confidence likely represent transiently structured elements or segments that adopt defined conformations upon binding RNA or protein partners. This structural characterization underscores how disease mutations in disordered proteins need not alter protein folding per se, but rather disrupt the delicate balance of localization and phase behavior that keeps these metastable proteins functional rather than pathogenic. --- ## Open Targets Disease Associations | Disease | Score | Data Sources | |---------|-------|--------------| | sporadic amyotrophic lateral sclerosis | 0.723 | literature, genetic_association, genetic_literature | | amyotrophic lateral sclerosis | 0.710 | literature, genetic_association, genetic_literature | | frontotemporal dementia with motor neuron disease | 0.667 | literature, animal_model, genetic_association, genetic_literature | | essential tremor | 0.557 | literature, genetic_association, genetic_literature | | juvenile amyotrophic lateral sclerosis | 0.527 | literature, genetic_association | | hereditary disease | 0.416 | literature, genetic_association | | liposarcoma | 0.387 | literature, somatic_mutation | | synovial sarcoma | 0.377 | literature, somatic_mutation | | undifferentiated pleomorphic sarcoma | 0.372 | literature, somatic_mutation | | extraskeletal myxoid chondrosarcoma | 0.371 | literature, somatic_mutation | *...and 901 more associations* --- ## AI Research Brief # Research Brief: FUS P525L Variant ## Pathogenic Mechanisms The FUS P525L variant represents a prototypical nuclear localization signal (NLS) region mutation that disrupts normal nucleocytoplasmic trafficking of the FUS protein. This proline-to-leucine substitution at position 525 impairs nuclear import, resulting in cytoplasmic mislocalization and subsequent aggregation. The variant directly impacts FUS's established molecular functions in chromatin binding, DNA binding, and identical protein binding, while disrupting critical biological processes including membraneless organelle assembly, mRNA stabilization, and ultimately promoting amyloid fibril formation. Literature findings indicate this variant causes particularly aggressive juvenile-onset ALS/FTD with characteristic FUS pathology. The mutation appears to trigger dual pathogenic mechanisms: loss of normal nuclear RNA-regulatory function and toxic gain-of-function through cytoplasmic aggregation. Additionally, emerging evidence suggests P525L disrupts lipid metabolism pathways, adding a metabolic dimension to the primarily RNA-centric pathogenesis model. The variant's location in the NLS region provides mechanistic clarity for the observed cytoplasmic redistribution and subsequent pathological cascades. ## Clinical Significance FUS P525L is associated with severe, early-onset ALS/FTD phenotypes, representing one of the most aggressive forms of FUS-related disease. The variant demonstrates clear pathogenic classification based on its recurrent identification in affected individuals and functional validation studies showing disrupted nuclear localization. Clinical-pathological characterization reveals distinctive FUS-positive cytoplasmic inclusions and accelerated disease progression compared to other ALS subtypes. The juvenile onset pattern associated with this variant contrasts markedly with typical adult-onset ALS, suggesting particularly potent pathogenic effects. The mutation's impact on protein-protein interactions with known FUS partners (TARDBP, SAFB, TAF15, RBMX, RALY) likely contributes to broader disruption of ribonucleoprotein complexes and RNA metabolism networks, amplifying downstream pathological consequences. ## Therapeutic Landscape The therapeutic landscape for FUS P525L centers on targeting protein aggregation and restoring normal cellular distribution. Structural analysis identifies a critical aggregation hotspot at residues 307-311 (aggregation score: 0.54), which has informed the computational design of candidate peptide CP-FUS-001 specifically targeting this region. This peptide inhibitor aims to disrupt the aggregation cascade by interfering with self-assembly at the identified high-risk sequence. The rationale for targeting residues 307-311 stems from their role in initiating the fibril formation pathway that becomes pathologically enhanced when FUS mislocalizes to the cytoplasm. Literature findings indicate emerging therapeutic strategies specifically designed for FUS-ALS, though the field remains in early stages. The combination of known aggregation-prone regions and the mechanistic understanding of NLS dysfunction provides a foundation for both peptide-based interventions and strategies to enhance nuclear import or reduce cytoplasmic aggregation burden. ## Research Directions Critical knowledge gaps remain regarding the precise temporal sequence of P525L-driven pathology and the relative contribution of loss-of-nuclear-function versus cytoplasmic gain-of-toxicity mechanisms. Priority research directions include: (1) validating CP-FUS-001 efficacy in cellular and animal models of FUS P525L, (2) elucidating the connection between lipid metabolism dysfunction and RNA dysregulation in disease progression, (3) identifying biomarkers for early detection given the juvenile onset pattern, and (4) determining whether therapeutic strategies should prioritize preventing aggregation, enhancing nuclear import, or combination approaches. The interaction network involving TARDBP and other RNA-binding proteins warrants investigation to understand potential convergent pathways with TDP-43 proteinopathies. Furthermore, structural studies examining how P525L affects the conformation of both the NLS region and distant domains could reveal allosteric effects relevant for therapeutic design. --- ## Agent Findings ### Literature (1) - **2026-07-16:** None of the provided papers are relevant to the FUS P525L protein variant or its association with ALS/FTD. The papers cover topics including gull diet analysis, epithelial morphogenesis, protein conformational modeling, CT phantom development, and precision health research survey design, none of which address FUS mutations, amyotrophic lateral sclerosis, or frontotemporal dementia. ### Clinical (1) - **2026-07-16:** ### Structural (1) - **2026-07-17:** AlphaFold structure update: Baseline check: 2 structure(s) found ### Synthesis (1) - **2026-07-17:** Synthesis of 5 findings (clinical, literature, peptides, structural, supplements): The FUS P525L variant represents a compelling therapeutic target with emerging evidence for peptide-... --- *Generated by [Clarity Protocol](https://clarityprotocol.io)* **Data Sources:** - Structure predictions: AlphaFold via ColabFold - Clinical variant data: ClinVar, gnomAD - Disease associations: Open Targets Platform - Research findings: AI agents (PubMed, clinical databases)